Skip to content

About Us
- About Us
- Team
- Careers
- Investors
- Collaborations
Our Technology
- Our Technology
- Our Device
Applications
News
Contact Us

Menu

About Us
- About Us
- Team
- Careers
- Investors
- Collaborations
Our Technology
- Our Technology
- Our Device
Applications
News
Contact Us

News

August 30, 2022

Santersus AG in combination with their institutional partners our extremely proud to present the newest findings regarding the success in the Ex Vivo lung perfusion studies.

REMOVAL-OF-NEUTROPHIL-EXTRACELLULAR Download

Related links

About Santersus

https://www.santersus.com/

About VolitionRx Limited

https://www.volition.com/

If you would like to learn more about our technology, please contact Santersus team at info@santersus.com

Santersus AG in combination with their institutional partners our extremely proud to present the newest findings regarding the success in the Ex Vivo lung perfusion studies.

August 30, 2022

Damage Associated Molecular Pattern (DAMP) removal during liver Normothermic Machine Perfusion facilitates organ rescue and reconditioning during preservation.

August 30, 2022

Santersus AG is excited to announce the commencement of its PhD program with the University of Edinburgh.

August 30, 2022

Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA

May 27, 2022

Ageing and rejuvenation

January 20, 2022

Page1 Page2

CONTACT US

Santersus AG,
c/o Lex Futura AG, Buckhauserstrasse
34, 8048 Zürich, Switzerland

+ 41 44 586 3656
info@santersus.com

LEGAL

View our full disclaimer